Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering's quazepam (Dormalin)

Executive Summary

Schering's quazepam (Dormalin): Licensed to Ivax subsidiary Baker Cummins Pharmaceuticals for manufacturing and marketing in the U.S. and Canada. Schering obtained approval for the sedative/hypnotic in late 1985, but never brought the product to market in the U.S. Baker Cummins said it will begin marketing the drug within the next several months. Schering has obtained an exclusive worldwide license from Baker Cummins for an undisclosed sustained release antibiotic that Baker is currently developing.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel